ESR1 and breast cancer: Estrogen receptor-positive (ER +)/HER2-negative (HER2-) breast cancers measuring ≤ 2 cm typically exhibit a favorable prognosis due to their distinct molecular features and behavior, with minimal rates of recurrence and distant metastasis within 5 years [1].